Volume | 273,478 |
|
|||||
News | - | ||||||
Day High | 16.48 | Low High |
|||||
Day Low | 14.49 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
CARGO Therapeutics Inc | CRGX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
15.17 | 14.49 | 16.48 | 16.29 | 14.95 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,338 | 273,478 | $ 15.27 | $ 4,175,459 | - | 13.14 - 16.48 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:27:35 | 1 | $ 16.30 | USD |
CARGO Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 629.98M | - | - | - | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
CARGO Therapeutics News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CRGX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 14.72 | 16.48 | 14.00 | 15.14 | 51,612 | 1.57 | 10.67% |
1 Month | 15.45 | 16.48 | 13.14 | 14.70 | 251,241 | 0.84 | 5.44% |
3 Months | 15.45 | 16.48 | 13.14 | 14.70 | 251,241 | 0.84 | 5.44% |
6 Months | 15.45 | 16.48 | 13.14 | 14.70 | 251,241 | 0.84 | 5.44% |
1 Year | 15.45 | 16.48 | 13.14 | 14.70 | 251,241 | 0.84 | 5.44% |
3 Years | 15.45 | 16.48 | 13.14 | 14.70 | 251,241 | 0.84 | 5.44% |
5 Years | 15.45 | 16.48 | 13.14 | 14.70 | 251,241 | 0.84 | 5.44% |
CARGO Therapeutics Description
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California. |